May 2, 2024
April 30, 2024
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
April 12, 2024
March 22, 2024
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
March 22, 2024
Displaying 11 - 20 of 20